Immucell Stock Price, News & Analysis

ImmuCell Corporation (Nasdaq: ICCC) is set to announce its unaudited financial results for Q2 2022 on August 11, 2022, after market close. A conference call will follow on August 12, 2022, at 9:00 AM ET to discuss these results and a regulatory update regarding Re-Tain®. The Company aims to enhance dairy and beef cattle health through its products, including First Defense® and Re-Tain®, which addresses subclinical mastitis without requiring milk discard. Investors are encouraged to review the updated Corporate Presentation on the Company’s website.

ImmuCell Corporation (Nasdaq: ICCC) announced that the FDA has issued a Technical Section Incomplete Letter concerning its New Animal Drug Application (NADA) for Re-Tain®. The letter pertains to the Chemistry, Manufacturing and Controls (CMC) Technical Section submitted earlier this year, with a focus on the need for a successful pre-approval re-inspection of the manufacturing facility. The company is preparing for this re-inspection and intends to submit a response in the upcoming quarter. Importantly, the FDA comments did not raise concerns about the safety or efficacy of Re-Tain®.

ImmuCell Corporation (Nasdaq: ICCC) announced preliminary, unaudited sales for Q2 2022, reporting $3.9 million, a 15% decrease from $4.5 million in Q2 2021. For the six-month period, sales rose to $9.9 million, up 14% from $8.6 million year-over-year. A supply disruption limited production, contributing to a backlog of $704,000. The company is focused on expanding manufacturing capacity and is seeking FDA approval for the new treatment Re-Tain®. A conference call for full Q2 results is scheduled for August 12, 2022.

ImmuCell Corporation (Nasdaq: ICCC) announced its 2022 Annual Meeting of Stockholders will be held virtually on June 15, 2022, at 3:00 PM ET, due to COVID-19 precautions. Stockholders of record as of April 14, 2022, can participate via live audio webcast or telephone. Voting in advance is encouraged. The Company also urged investors to review their recent Form 10-Q filed on May 12, 2022, for insights into financial performance. ImmuCell focuses on improving dairy and beef cattle health through innovative products like First Defense® and Re-Tain®.

ImmuCell Corporation (Nasdaq: ICCC) reported a significant 46% increase in Q1 2022 product sales, reaching $6 million, compared to $4.1 million in Q1 2021. This surge has enhanced cash flows and net income, which stood at $736,000 or $0.09 per diluted share. Gross margins improved to 52%. The company has ramped up production capacity and anticipates an FDA response regarding Re-Tain® by Q3 2022. Cash reserves rose to $11.8 million, while net working capital reached $15.9 million, reflecting a healthy financial position.

ImmuCell Corporation (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ending March 31, 2022, after market close on May 12, 2022. A conference call is scheduled for May 13, 2022, at 9:00 AM ET to discuss the results. Dr. Joseph H. Crabb will participate to cover the company's science and technology. The Quarterly Report on Form 10-Q will be available post-market close on May 12, 2022, along with a corporate presentation on ImmuCell's business.

ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as the new Commercial Leader of Stakeholder Engagement, aimed at launching their innovative product, Re-Tain®, pending FDA approval. Dr. Wustenberg brings significant experience in the dairy industry, having held various leadership roles, including at Tillamook County Creamery. His focus will be on enhancing communication and research efforts to foster product acceptance, benefiting both Re-Tain® and the First Defense® product line. The company is set to discuss its financial results on May 13, 2022.

ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as Commercial Leader of Stakeholder Engagement. Dr. Wustenberg brings extensive experience from his previous roles, including Vice President of Sustainability at Tillamook County Creamery. He will focus on the upcoming launch of Re-Tain®, pending FDA approval, and enhancing the market presence of First Defense®. The company aims to improve dairy producer profitability through these initiatives, leveraging Dr. Wustenberg's industry expertise to strengthen its sales and marketing strategy.

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales of $6.0 million for Q1 2022, a 46% increase from $4.1 million in Q1 2021. This marks a record high for any quarter. The company is expanding its First Defense manufacturing capacity from $16.5 million to $35 million, with annualized output reaching $23.8 million. ImmuCell is also awaiting FDA approval for the Re-Tain product, with a response expected in Q3 2022.